<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823783</url>
  </required_header>
  <id_info>
    <org_study_id>8948</org_study_id>
    <nct_id>NCT01823783</nct_id>
  </id_info>
  <brief_title>Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction in Duchenne Muscular Dystrophy</brief_title>
  <official_title>Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction : Potential Links and Targeted Pharmacotherapy in Duchenne Muscular Dystrophy (DMD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Duchenne muscular dystrophy (DMD) is the most common and devastating form of muscular
      dystrophy, caused by an X-chromosome gene mutation resulting in the absence of the protein
      dystrophin. Gene therapy by exon skipping or stop codon read-through and cell therapy are at
      the stage of clinical assays with very promising results. Nevertheless, they will not allow a
      complete cure of DMD patients and they will concern only specific types of mutations. It is
      therefore crucial to develop other therapeutic strategies related to the natural history of
      the disease and targeted not on the dystrophin itself, but on the consequences of its
      absence.

      Another crucial pathophysiological pathway in DMD is muscle cell calcium homeostasis,
      particularly via the ryanodine recepteur (RyR1).

      Our study focus on the relationship between endomysial fibrosis, abnormal inflammation
      response and calcium homeostasis dysfunction which are not entirely established in DMD.

      The identification of the biological mechanisms that play a role in the severity of the
      phenotype, particularly endomysial fibrosis, should allow the development of targeted
      pharmacotherapy as a complementary strategy for the future treatment of DMD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2012</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of endomysial fibrosis</measure>
    <time_frame>1 day (biopsy day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>quantification of the muscle inflammation</measure>
    <time_frame>1 day (biopsy day)</time_frame>
    <description>Measure of the protein (Immunofluorescence and western blot) and mRNA (qRT-PCR) expression of the following markers of muscular inflammation response
Presence and quantification of cellular partners of inflammation and muscle regeneration (M1 (CD68/KP1) and M2 (CD206) macrophages, quiescent and activated satellite cells (CD56/NCAM) and endothelial cells (CD31/PECAM-1)).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Duchenne Muscular Distrophy (DMD)</condition>
  <arm_group>
    <arm_group_label>DMD infant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Muscle biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control infant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Muscle biopsy (during lower limb operation surgery for pure orthopedic causes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscle biopsy</intervention_name>
    <description>Muscle biopsy</description>
    <arm_group_label>DMD infant</arm_group_label>
    <arm_group_label>Control infant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Boy between 2 to 15 years old.

          -  Lack of any infectious disease in the last week before the study.

          -  Consent form signed by parents.

        Inclusion Criteria for DMD infant

          -  Clinical suspicion of Duchenne Muscular Dystrophy

        Inclusion Criteria for Control healthy Infant

          -  Lack of any antecedent of congenital cardiac, pulmonary or muscular disease including
             DMD.

        Exclusion Criteria:

          -  Subjects who are unable or unwilling to tolerate study constraints

          -  Parents of the subject unable or unwilling to undergo informed consent

          -  Subject with no rights from the national health insurance programme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François RIVIER, PU PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>uh montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François RIVIER, PU PH</last_name>
    <email>f-rivier@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Matecki, PU PH</last_name>
    <email>s-matecki@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UH Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Epsil</last_name>
      <email>caroline.epsil@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline Epsil, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie Cuisset, PH</last_name>
      <email>jean-marie.cuisset@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marie Cuisset, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Chauveton</last_name>
      <email>c-chauveton@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>François RIVIER, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Matecki, PU PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Meyer, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrike Walther-Louvier, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérome Cottalorda, PU PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle DESGUERRE, PU PH</last_name>
      <email>isabelle.desguerre@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Desguerre, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Sabouraud, PH</last_name>
      <email>psabouraud@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal Sabouraud, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CHABRIER, PH</last_name>
      <email>stephane.chabrier@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane CHABRIER, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonard Feasson, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude Cances, PU PH</last_name>
      <email>cances.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Claude Cances, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2013</study_first_submitted>
  <study_first_submitted_qc>March 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular distrophy</keyword>
  <keyword>Endomysial Fibrosis</keyword>
  <keyword>Muscular Inflammatory Response</keyword>
  <keyword>Calcium Homeostasis Dysfunction</keyword>
  <keyword>Muscle biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

